Form 4: BioLife Solutions CFO Sells Shares Under 10b5-1 Trading Plan

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 581 shares of common stock at $27.2 per share on November 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Troy Wichterman, the Chief Financial Officer of BioLife Solutions, sold 581 shares of the company's common stock on November 26, 2024.
• The sale was executed at a price of $27.2 per share.
• This transaction was conducted under a pre-existing Rule 10b5-1(c) trading plan.
• The trading plan was adopted on February 24, 2022.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-existing trading plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading. It is common for executives to sell shares to cover tax obligations related to vesting of restricted stock.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and life sciences sectors, such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR).
• These plans allow executives to sell shares at predetermined times and prices, avoiding potential accusations of insider trading.
• The sale of shares to cover tax obligations is also a standard practice.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, Form 4, 10b5-1 plan, stock sale, CFO, Troy Wichterman, equity securities